Table 2.
Diagram comparing the differences between glycosylation and glycation.
| Feature | Glycosylation | Glycation/AGEs |
|---|---|---|
| Catalytic mechanism | Enzymatic reaction (catalyzed synergistically by glycosyltransferases and glycosidases) | Non-enzymatic spontaneous chemical reaction (Maillard reaction) |
| Site of occurrence | Endoplasmic Reticulum (ER), Golgi apparatus (N-glycosylation, classical O-glycosylation); Cytoplasm, Nucleus (O-GlcNAcylation) | Occurs in both intracellular and extracellular environments; significantly accelerated in microenvironments with high glucose and high oxidative stress |
| Sugar dono | Activated sugar derivatives, including UDP-monosaccharides, GDP-monosaccharides, dolichol pyrophosphate-linked oligosaccharides, etc. | Free reducing sugars (e.g., glucose, fructose), and reactive dicarbonyl compounds generated from glycoxidation and lipid peroxidation |
| Linkage type | N-glycosidic bond (Asparagine, Asn) or O-glycosidic bond (Serine/Threonine, Ser/Thr) | Non-specific covalent modification, mainly occurring on Lysine (Lys), Arginine (Arg) residues and N-terminal amino groups of proteins; no consensus sequence motif |
| Reversibility | O-GlcNAcylation is a fully reversible dynamic cycle; the synthesis process of N-glycosylation and classical O-glycosylation can be trimmed by glycosidases, while removal of mature glycans is generally irreversible | Covalent modification and cross-linking of proteins by advanced glycation end products (AGEs) are completely irreversible; only early reaction intermediates (Schiff bases, Amadori products) are reversible |
| Physiological function | Involved in multiple core physiological processes: protein folding quality control, intracellular trafficking, membrane localization, cell-cell recognition, signal transduction, etc. | Non-specific damaging modification at physiological levels; no clear physiological function identified to date. Accumulates abundantly under pathological conditions and mediates cytotoxicity and tissue damage |
| Role in alzheimer's disease (AD) | Has a dual role: Downregulation of O-GlcNAcylation promotes hyperphosphorylation and aggregation of tau protein, exerting neurotoxicity; physiological levels of glycosylation maintain normal metabolism of amyloid precursor protein (APP) and neuronal function, exerting neuroprotective effects | Clear neurotoxicity: Promotes abnormal aggregation and deposition of Aβ and tau proteins; mediates chronic neuroinflammation and oxidative stress via the receptor for advanced glycation end products (RAGE), driving AD pathological progression |
| Therapeutic strategy direction | Upregulate protein glycosylation levels, e.g., increase O-GlcNAcylation via O-GlcNAcase (OGA) inhibitors | Inhibit glycation reactions, scavenge preformed AGEs, and block RAGE-mediated signaling pathways |